Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Johnson & Johnson

Novavax (NASDAQ: NVAX) stock rallied by over 10% after the U.S. Food and Drug Administration and the U.S. Centers for Disease Control paused the rollout of Johnson & Johnson's Covid-19 vaccine in the U.S. following some rare, yet severe incidents of blood clotting.

Will Novavax Stock Benefit From Johnson & Johnson's Covid Vaccine Woes?

European filings will likely come sooner than the biotech's U.S. submission.

How Soon Will Novavax File for Emergency Use Authorization for Its COVID Vaccine?

GAITHERSBURG, Md., April 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce.

Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

Palantir Technologies

Palantir Technologies Inc (NYSE: PLTR) shares are trading lower by 5.8% at $23.94, despite the company earlier Wednesday announcing a partnership with Clarifai to deliver AI and machine learning algorithms on Palantir's data management platform. Palantir delivers big data analytics software solutions to United States government projects.

What's Going On With Palantir Stock And Novavax Stock Today?

Moderna

Researchers said that a U.K. study of using different Covid-19 vaccines in two-dose inoculations is now expanded to include vaccines made by Moderna Inc (NASDAQ: MRNA) and Novavax Inc (NASDAQ: NVAX), Reuters reports. The trial, known as the Com-Cov study, was first launched in February this year to assess whether giving the first dose of one type of COVID-19 shot and the second dose of another elicits an immune response as good as using two doses of the same vaccine.

UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots

Novavax said in March its coronavirus vaccine was 96.4% effective in a Phase 3 test. It's also effective against variants.

Is Novavax Stock A Buy On Its Leading Covid Vaccine Effectiveness?

The first leg of this trial experimented with replacing the second shot of the AstraZeneca vaccine with a dose of Pfizer's mRNA jab to see it provided a stronger defense against Covid.

U.K. Expands Its Mix-And-Match Covid-19 Vaccine Trial To Include Moderna And Novavax Shots

Why Are Participants in Novavax's COVID Vaccine Study Receiving 2 Extra Shots?

Nano-X Imaging

Trupanion

Analysts' enthusiasm for these stocks appears to be justified.

3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More

A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.

Moderna and Novavax added to ‘mix and match' COVID-19 vaccine trial

Novavax Inc. said late Tuesday that Chief Financial Officer Greg Covino is stepping down for personal reasons, but will remain connected to the company as an executive adviser. The biotech also said it promoted Gale E.

Novavax CFO to step down, biotech company says

GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ --  Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E.

Novavax Announces Leadership Updates

BioNTech SE

Bad news for J&J could be good news for these biotechs.

Why Novavax and BioNTech Stocks Are Jumping Today

Pfizer

Johnson & Johnson's (NYSE: JNJ) pain has proved to be gain for other vaccine companies, including BioNTech SE (NASDAQ: BNTX), Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX). What Happened: The Food and Drug Administration and the Centers for Disease Control and Prevention announced it's recommending pausing of the use of J&J's single-shot coronavirus vaccine, attributing the decision on incidents of severe, atypical blood clots.

Why Vaccine Stocks Pfizer, BioNTech, Moderna And Novavax Are Higher

AstraZeneca

Regeneron Pharmaceuticals

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

There's a good argument to be made that it is.

Is Novavax Actually a Value Stock?

Biogen

iTeos Therapeutics, Inc.

Upcoming events could send these stocks screaming higher or lower.

3 Biotech Stocks With Big Catalysts Around the Corner

Datadog

Skillz

Trulieve Cannabis Corp.

Teladoc

These rapidly growing companies appear to be screaming bargains.

5 Growth Stocks With 43% to 70% Upside, According to Wall Street

Covid-19 vaccine stocks have had a solid run, driven by the urgency to end the pandemic and the unprecedented speed at which companies have developed highly effective vaccines. Our theme of Covid-19 Vaccine Stocks - which includes Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), Johnson & Johnson.

Moderna, Novavax: Are Covid Vaccine Stocks Still Worth Investing In?

GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference.

Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference

Novavax stock has declined by about 20% over the last ten trading days, although it remained roughly flat over the last week. The stock currently trades at about $177 per share.

Has Novavax Stock Run Its Course?

This Vaccine Maker May Be Next to Go After the Kids' Market

Novavax Inc (NASDAQ: NVAX) said that participants in its ongoing COVID-19 vaccine trials in South Africa and the U.K. could receive additional shots, ensuring those who received a placebo can also get the active vaccine. Allowing volunteers to crossover to the active vaccine will enable participants to continue in trials and remain blinded.

Novavax Allows Participants On Placebo Arm To Get COVID-19 Vaccine In Trials

Novavax Inc. said late Monday it plans to expand its COVID-19 vaccine trials to include children and teens by the second quarter. The biotech also said it will start crossover trials in its ongoing trials of the vaccine candidate.

Novavax to expand COVID-19 vaccine trials to children, teens

Crossover allows participants to continue in trials and remain blinded Ensures that all trial participants receive active vaccine South Africa and UK crossover arms initiated; US/Mexico PREVENT-19 crossover planned GAITHERSBURG, Md., April 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company's COVID-19 vaccine candidate.

News for Novavax Stock (NVAX)